

## Accepted Manuscript

A pharmacology guided approach for setting limits on product-related impurities for bispecific antibody manufacturing

Sharmila Rajan, Junichiro Sonoda, Timothy Tully, Ambrose J. Williams, Feng Yang, Frank Macchi, Terry Hudson, Mark Z. Chen, Shannon Liu, Nicole Valle, Kyra Cowan, Thomas Gelzleichter



PII: S1056-8719(17)30534-8

DOI: doi:[10.1016/j.vascn.2018.04.002](https://doi.org/10.1016/j.vascn.2018.04.002)

Reference: JPM 6517

To appear in: *Journal of Pharmacological and Toxicological Methods*

Received date: 7 November 2017

Revised date: 8 March 2018

Accepted date: 11 April 2018

Please cite this article as: Sharmila Rajan, Junichiro Sonoda, Timothy Tully, Ambrose J. Williams, Feng Yang, Frank Macchi, Terry Hudson, Mark Z. Chen, Shannon Liu, Nicole Valle, Kyra Cowan, Thomas Gelzleichter, A pharmacology guided approach for setting limits on product-related impurities for bispecific antibody manufacturing. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. *Jpm*(2017), doi:[10.1016/j.vascn.2018.04.002](https://doi.org/10.1016/j.vascn.2018.04.002)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

A Pharmacology Guided Approach for Setting Limits on Product-Related Impurities for Bispecific Antibody Manufacturing

Sharmila Rajan<sup>1,1,\*</sup> rajan.sharmila@gene.com, Junichiro Sonoda<sup>2,1,\*\*\*</sup>

sonoda.junichiro@gene.com, Timothy Tully<sup>3</sup>, Ambrose J Williams<sup>3</sup>, Feng Yang<sup>3</sup>, Frank Macchi<sup>3</sup>, Terry Hudson<sup>3</sup>, Mark Z Chen<sup>2</sup>, Shannon Liu<sup>4</sup>, Nicole Valle<sup>4</sup>, Kyra Cowan<sup>5</sup>, Thomas Gelzleichter<sup>6,\*</sup> gelzleichter.tom@gene.com

<sup>1</sup>Preclinical and Translational Pharmacokinetics, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080.

<sup>2</sup>Molecular Biology, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080.

<sup>3</sup>Global Technical Development, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080.

<sup>4</sup>Non clinical Operations, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080.

<sup>5</sup>Bio analytical Sciences, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080.

<sup>6</sup>Safety Assessment, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080.

\* **Correspondence to:** Safety Assessment, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.

\*\* **Correspondence to:** Sharmila Rajan, Preclinical and Translational Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, CA-94080

\*\*\* **Correspondence to:** Molecular Biology, Genentech, Inc, 1 DNA Way, South San Francisco, CA-94080

## Abstract

Introduction: bFKB1 is a humanized bispecific IgG1 antibody, created by conjoining an anti-Fibroblast Growth Factor Receptor 1 (FGFR1) half-antibody to an anti-Klotho $\beta$  (KLB) half-

---

<sup>1</sup> S Rajan and J Sonoda contributed equally to this work

Download English Version:

<https://daneshyari.com/en/article/8533704>

Download Persian Version:

<https://daneshyari.com/article/8533704>

[Daneshyari.com](https://daneshyari.com)